What question did this study set out to answer?

This research aims to assess the effect of antiemetic prophylaxis on dose modifications of trastuzumab deruxtecan in patients with HER2-positive and HER2-low breast cancer.

January 21, 2026Future Oncology0 citations

Impact of antiemetic prophylaxis on reducing trastuzumab deruxtecan dose modifications in HER2+/HER2-low breast cancer

JSJunghoon ShinNational Oceanic and Atmospheric Administration JKJiyeon KimSungkyunkwan University HAHee Kyung AhnSungkyunkwan University

Key Points

This research aims to assess the effect of antiemetic prophylaxis on dose modifications of trastuzumab deruxtecan in patients with HER2-positive and HER2-low breast cancer.
Evaluated the role of antiemetic prophylaxis in treatment regimens.
Assessed dosing adjustments of trastuzumab deruxtecan (T-DXd).
Focused on patients diagnosed with HER2-positive or HER2-low advanced breast cancer.
Upfront antiemetic prophylaxis may help maintain prescribed T-DXd doses.
Reduction in dose modifications observed among treated patients.

Abstract

These findings suggest that upfront TAR may help maintain the dosing of T-DXd in patients with HER2-positive or HER2-low ABC.

问 AI

Bookmark

View Full Paper